SUMMARY Antibodies to rheumatoid arthritis nuclear antigen (RANA) are detected by immunodiffusion (ID) and immunofluorescence (IF), though reports of the identity of the antigen(s) have been conflicting. In this study it is shown conclusively that ID and IF anti-RANA react with epitopes on Epstein-Barr nuclear antigen I (EBNA-1) and that the major epitope detected by immunofluorescence is represented by a synthetic peptide, P62, corresponding to part of EBNA-1. In an enzyme linked immunosorbent assay (ELISA) anti-P62 antibodies in 35 rheumatoid arthritis sera were threefold higher than those of 35 age and sex matched controls, with the highest levels occurring in young patients with active joint disease.
Anitibodies to rhelinatoid (arthritis tiliclear antigei in RA 271 epitopes on the same polypeptide. These data were challenged by Sculley and his colleagues, 20 21 who confirmed that RA sera reacted with EBNA-1 but that the greatest difference between RA and normal sera was in a reaction with a higher molecular weight (94 kilodalton) polypeptide that they identified as EBNA-2,2' which correlated with antibodies to RANA by immunofluorescence. Based on this evidence they suggested that EBNA-2 was the target for anti-RANA antibodies.
A recent report described the use of several synthetic peptides corresponding to sequences in EBNA-1 in enzyme linked immunosorbent assays (ELISA) for measuring anti-EBNA antibodies.--Several peptides reacted strongly with RA sera, but the highest levels of binding and the greatest difference between RA and normal sera were found with a peptide, P62, containing 20 amino acids, corresponding to part of the internal repeat sequence of EBNA-1. In that study, however, the patients and controls were not age matched, nor was there any attempt to define whether the antibodies reacting with P62 had anti-RANA or anti-EBNA specificities, or both.
The purpose of this study was to use P62 to characterise antibodies reacting with RANA and EBNA-1 by immunofluorescence, Western blot, immunodiffusion, and ELISA in patients with RA and healthy controls. Because each of the antibody systems is operationally defined we have chosen the following nomenclature for each antibody system: anti-EBNA detected by anticomplementary immunofluorescence is termed ACIF anti-EBNA, and anti-EBNA-1 refers to antibodies detected by Western blot. Anti-RANA by indirect immunofluorescence is termed IF anti-RANA, and by immunodiffusion ID anti-RANA. The term anti-P62 refers to specific antibodies detected by ELISA. We have also examined antibodies to P62 in a group of patients with RA and compared the results with those for age and sex matched controls to see whether, like anti-RANA, high titres of these antibodies are found in RA. out in 2 mmx5 mmx2 mm slices. The four opposite the well containing WI-L2 extract and the four opposite that containing P3HR-1 were each amalgamated as WI-L2 and P3HR-1 precipitins respectively. Slices from two areas of gel, each 2 mmx 10 mmx2 mm, immediately above and below the P3HR-1 wells in which no precipitins were seen. were amalgamated as the control. The precipitins were prepared by boiling them twice with 50 ld concentrated starting buffer and quickly applying them to a polyacrylamide gel before the agarose reset. For the immunoblotting of multiple fractions on one antigen the cassette described by (Fig. 2) . There was only a very weak reaction with EBNA-1 in gel cut from an area in which there was no visible precipitin. There was also a reaction with HSA conjugated to P62, migrating as a diffuse band between 80 and 100 kilodaltons with some higher molecular weight bands. This confirmed that P62 was immunoreactive on blotting and that there were on average 10 P62 peptides on each HSA molecule, accounting for its increased molecular weight. REACTION coupled to alanine or to poly-i-lysine (Table 2) . These experiments led us to adopt the following protocol for examining further sera. Each serum was passed first through the glycine conjugated column to absorb antiglvcine antibodies, then through the (Fig. 4) . Two sera. RA 3 and 4. were deliberatelv selected for the presence of high titre antinuclear antibodies (ANA), one homogeneous and one speckled, which obscured ainy specific RANA staining. The ANA were recovered in the flow through, whereas the eluates. which had been completelv cleared of ANA staining, showed the characteristic RANA staining pattern. Two further sera. RA 5 and 6. were tested because they were IF anti-RANA positive but ACIF anti-EBNA negative.
It is of interest that in one of these the eluate from the glycine column contained anti-RANA activity.
Affinity chromatography was also used to characterise anti-RANA antibodies detected by immunodiffusion. Because this assay requires higher concentrations of serum to produce a precipitin. a serum dilution of 1:4 and column fractions equivalent to a serum dilution of 1:4 were used. ID anti-RANA was detected in the serum and the flow through but not in the eluates from either the glycine or the P62 column. There was depletion of ainti-RANA activity in the flow through from the columns, however, in that the titre fell from 1/128 to 1/16. In addition, we attempted to purify atnti-RANA antibodies by elutioni from the P62 column without preabsorbing with glycine, and again no precipitins were seen in the eluate. We also tested P62, P62 con.jugated to KLH, and P62 conjugated to HSA as antigens on immunodiffusion. At concenitrationls of 2, 20, and 200 rig/ml neither P62 alone nor the IISA or KLH conjugates formed precipitins with three anti-RANA sera (Nos 1, 2, and 3) or with the eluIate recovered from the P62 column (Fig. 5) .
By ELISA, serum No 2 bound to P62 alt dilutions greater than 1:30 000 and was used as the standard serum. With screeningt dilutionis of 1:20 the RA sera were found to contain anti-P62 antibodies in titres twofold higher than those of the age and sex matched controls (not shown), and at a screening dilution of 1:320, the titres were 3-5 times higher (Fig. 6) . Of the 35 patients with RA tested, very high levels (greater than five standalrd deviations above normal) were found in four. All four were young (aged less than 35), DR4 positive, and had active joint disease. Onlv one was receiving second line antirheumatic treatment. Discussion This study has conclusivcly shown that both IF and ID anti-RANA antibodics react with the EBNA-1. The recent suggestion that anti-RANA antibodies react with EBNA-2 was based on correlative data, and is contradicted by our findings that both ID and IF RANA are detectable in P31IR-1, a cell line in which the EBNA-2 gene has been deleted,~7 and by the finding that a serum lacking EBNA-2 antibodies reacted with RANA both by immunofluorescence and immunodiffusion. The reatction with EBNA-1 was confirmed by immunoblotting RANA precipitins. A similar experimenit was also reported by Billings et al with the samc result, though they did not illustrate their findings in a figure."' Our data suggest that P62 contains the major epitope recognised by IF anti-RANA antibodies. Antibodies were depleted by a single passage through the P62 column and then recovered from the eluate in six RA sera. This suggests that the short amino acid sequence contatins most if not all of the epitopes recognised by IF anti-RANA. This may be because P62 contains all possible epitopes on the IR3 region of the EBNA-1 peptide: it has two glycine triplets, two glycine doublets, and three single glycine residues each separated from each other by single alanine residues.
In contrast with IF anti-RANA, ACIF anti-EBNA did not appear to react with P62, though it is possible that treatmllenit with 3 M guanidillne cxcn after dialysis back into saline, affected the complement fixing abilities of the antibody. This possihilitv is supported by the recoverv of soille ACIl anti-EBNA reatctivity in the acid eluKate. Nevertheless. the recovery of ACIF aniti-EBNA in the flow through sugg,ests that antibodies cletected bx this technique have a more diffuse reactivitv. includiCg epitopes on EBNA-2. 7 These findinigs also explain discrepatncies betweeti anti-RANA anltd aniti-EBNA which have been obserxved in sera fromli patients with RA (includinig two ser-a in this stLid\ ). fromii those ,With Burkitt's lymphoma, and in those from patients recovering from infectious mononucleosis.
The relation between ID anti-RANA and P62 was not so clear cut. We were not ahle to show a precipitin reaction between affinity purified anti-P62 antibodies and WI-L2 extract and there were no precipitins detected between P62 (alone or conijugalted to proteins such as KLH or album,1in) and aIIti-RANA positive reference sera. The tall in titre in the flow through. however, supports our cearlielr suggestion that more thain one atntigen maly play al part in the RANA precipitin reaction, and that once of these mrav be represented by P62.4 ' The exact Antibodies to rhelimatoid arthritis nuiclear antigen in RA 277 specificity of ID anti-RANA antibodies remains unknown, though we can be certain that major epitopes lie on EBNA-1. Our findings also challenge the assumption that ID anti-RANA and IF anti-RANA are the same.
We have previously suggested that the higher titres of ID anti-RANA antibodies in RA, and the finding of anti-RANA antibodies in sera from patients free of EBV infection, could be due to cross reactive autoantibodies. In this study cross reactions were found between antibodies binding to a glycine conjugated column (antiglycine antibodies), anti-P62, and anti-EBNA-1 by immunoblotting. Specificity was proved by showing no binding to columns conjugated with alanine or lysine. Such a cross reaction is perhaps not surprising when it is considered that 13 of the 20 amino acids which comprise P62 are glycine residues. It is possible that such a cross reaction could account for the range 
